Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 177 of the 178 references it cites were found in a registry or an index.

Computational Approaches in Theranostics: Mining and Predicting Cancer Data

Open access

Abstract

The ability to understand the complexity of cancer-related data has been prompted by the applications of (1) computer and data sciences, including data mining, predictive analytics, machine learning, and artificial intelligence, and (2) advances in imaging technology and probe development. Computational modelling and simulation are systematic and cost-effective tools able to identify important temporal/spatial patterns (and relationships), characterize distinct molecular features of cancer states, and address other relevant aspects, including tumor detection and heterogeneity, progression and metastasis, and drug resistance. These approaches have provided invaluable insights for improving the experimental design of therapeutic delivery systems and for increasing the translational value of the results obtained from early and preclinical studies. The big question is: Could cancer theranostics be determined and controlled in silico? This review describes the recent progress in the development of computational models and methods used to facilitate research on the molecular basis of cancer and on the respective diagnosis and optimized treatment, with particular emphasis on the design and optimization of theranostic systems. The current role of computational approaches is providing innovative, incremental, and complementary data-driven solutions for the prediction, simplification, and characterization of cancer and intrinsic mechanisms, and to promote new data-intensive, accurate diagnostics and therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics11030119

Cites

177 of 177 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic illustration of the refinement process involving several integrative approaches and powered by new income and technologies. Adapted from [48]. Copyright Taylor & Francis, 2016.
Figure 1 Schematic illustration of the refinement process involving several integrative approaches and powered by new income and technologies. Adapted from [48]. Copyright Taylor & Francis, 2016.CC BY · PubMed Central
Figure 2 Schematic representation of the iterative optimization workflow, reflecting the data integration/analysis and the development/optimization processes of the computational model. Reprinted from [65] under a CC BY 4.0 License. Copyright Ogilvie, L.A., Kovachev, A., Wierling, C., Lange, B.M.H. and Lehrach, H., 2017.
Figure 2 Schematic representation of the iterative optimization workflow, reflecting the data integration/analysis and the development/optimization processes of the computational model. Reprinted from [65] under a CC BY 4.0 License. Copyright Ogilvie, L.A., Kovachev, A., Wierling, C., Lange, B.M.H. and Lehrach, H., 2017.CC BY · PubMed Central
Figure 3 Representative 3D snapshots of the tumor response over time (t = 40, 80, 120, 200 h) and considering three drug-treatment scenarios: doxorubicin alone (Dox), sunitinib alone, and treatment with combined drugs (Dox + sunitinib). Reprinted from [111] under a CC BY 2.0 License. Copyright Wang, J., Zhang, L., Jing, C., Ye, G., Wu, H., Miao, H., Wu, Y. and Zhou, X., 2013.
Figure 3 Representative 3D snapshots of the tumor response over time (t = 40, 80, 120, 200 h) and considering three drug-treatment scenarios: doxorubicin alone (Dox), sunitinib alone, and treatment with combined drugs (Dox + sunitinib). Reprinted from [111] under a CC BY 2.0 License. Copyright Wang, J., Zhang, L., Jing, C., Ye, G., Wu, H., Miao, H., Wu, Y. and Zhou, X., 2013.CC BY · PubMed Central
Figure 4 A schematic representation of the two-dimensional projection of cellular landscape of tumor microenvironment. (a) Data from The Cancer Genome Atlas (TCGA) were analyzed and represented in a two-dimensional tumor microenvironment landscape map resorting to t-distributed stochastic neighborhood embedding (t-SNE) based on the scores reflecting the enrichment of cell types. (b) Gradient color representing the tumor metabolism index (TMI) of each sample, showing that hypometabolic samples are placed within populations with low values. (c) Circular dendrogram for the groups identified by hierarchical cluster analysis. (d) Two-dimensional map of the tumor microenvironment landscape reflecting the similarity between samples. (e) Selected clusters displaying significantly different tumor metabolic index (TMI). (f) Two-dimensional map of the tumor microenvironment landscape with the ImmuneScore information. (g) ImmuneScores were significantly different between the clusters. (h) A composed view of the results including the heatmap showing the scores of the enrichment of each immune cell type, the tumor metabolism index, the groups identified based on immune cellular heterogeneity, lung adenocarcinoma subtypes, and ImmuneScore. Reprinted from [113] under a CC BY-NC 4.0 license. Copyright Ivyspring International Publisher, 2018.
Figure 4 A schematic representation of the two-dimensional projection of cellular landscape of tumor microenvironment. (a) Data from The Cancer Genome Atlas (TCGA) were analyzed and represented in a two-dimensional tumor microenvironment landscape map resorting to t-distributed stochastic neighborhood embedding (t-SNE) based on the scores reflecting the enrichment of cell types. (b) Gradient color representing the tumor metabolism index (TMI) of each sample, showing that hypometabolic samples are placed within populations with low values. (c) Circular dendrogram for the groups identified by hierarchical cluster analysis. (d) Two-dimensional map of the tumor microenvironment landscape reflecting the similarity between samples. (e) Selected clusters displaying significantly different tumor metabolic index (TMI). (f) Two-dimensional map of the tumor microenvironment landscape with the ImmuneScore information. (g) ImmuneScores were significantly different between the clusters. (h) A composed view of the results including the heatmap showing the scores of the enrichment of each immune cell type, the tumor metabolism index, the groups identified based on immune cellular heterogeneity, lung adenocarcinoma subtypes, and ImmuneScore. Reprinted from [113] under a CC BY-NC 4.0 license. Copyright Ivyspring International Publisher, 2018.CC BY · PubMed Central
Figure 5 (a) Scheme of the modelling workflow, (b) Simulation dynamics results of the tumor growth in a virtual mouse after treatment with OT-1 T-cells and anti-CD137 monoclonal antibody, obtained at days 7, 41, 16, 20, 24, and 28 (from upper-left to lower-right). The effect of anti-CD137 in tumor infiltration is confirmed by the increased TC cell cytotoxicity and by the chemotaxis gradients. (c,d) Model prediction results obtained from the in silico study suggesting that the combined therapy with OT-1 T-cells and anti-CD137 monoclonal antibody) was not efficient in eliminating murine B16OVA melanoma with no expression of CD137 on endothelium (c). When comparing with wild-type in silico mice, the CD8 T cell infiltration was drastically reduced and delayed in time (d). Adapted from [116] under a CC BY 4.0 License. Copyright Pappalardo, F., Forero, I.M., Pennisi, M., Palazon, A., Melero, I. and Motta S., 2011.
Figure 5 (a) Scheme of the modelling workflow, (b) Simulation dynamics results of the tumor growth in a virtual mouse after treatment with OT-1 T-cells and anti-CD137 monoclonal antibody, obtained at days 7, 41, 16, 20, 24, and 28 (from upper-left to lower-right). The effect of anti-CD137 in tumor infiltration is confirmed by the increased TC cell cytotoxicity and by the chemotaxis gradients. (c,d) Model prediction results obtained from the in silico study suggesting that the combined therapy with OT-1 T-cells and anti-CD137 monoclonal antibody) was not efficient in eliminating murine B16OVA melanoma with no expression of CD137 on endothelium (c). When comparing with wild-type in silico mice, the CD8 T cell infiltration was drastically reduced and delayed in time (d). Adapted from [116] under a CC BY 4.0 License. Copyright Pappalardo, F., Forero, I.M., Pennisi, M., Palazon, A., Melero, I. and Motta S., 2011.CC BY · PubMed Central
Figure 6 Membrane interaction and internalization of the polyarabic-coated magnetite nanoparticle, MAG-ARA. (a) Initial configuration of MAR-ARA in vacuum. (b) Final configuration of MAR-ARA in contact with a dipalmitoyl phosphatidylcholine (DPPC) bilayer. (c) Example of the interactions of l-arabinose and d-galactose with DPPC. (d) Confocal fluorescence image and a bright filed image from human breast cancer cells incubated with MAG-ARA, left, and control nanoparticles, right. Reprinted from [44] under a CC BY 4.0 license. Copyright Patitsa, M., Karathanou, K., Kanaki, Z., Tzioga, L., Pippa, N., Demetzos, C., Verganelakis, D.A., Cournia, Z. and Klinakis, A., 2017.
Figure 6 Membrane interaction and internalization of the polyarabic-coated magnetite nanoparticle, MAG-ARA. (a) Initial configuration of MAR-ARA in vacuum. (b) Final configuration of MAR-ARA in contact with a dipalmitoyl phosphatidylcholine (DPPC) bilayer. (c) Example of the interactions of l-arabinose and d-galactose with DPPC. (d) Confocal fluorescence image and a bright filed image from human breast cancer cells incubated with MAG-ARA, left, and control nanoparticles, right. Reprinted from [44] under a CC BY 4.0 license. Copyright Patitsa, M., Karathanou, K., Kanaki, Z., Tzioga, L., Pippa, N., Demetzos, C., Verganelakis, D.A., Cournia, Z. and Klinakis, A., 2017.CC BY · PubMed Central
Figure 7 (A) UV−vis absorption spectra of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs at different (AEMA):(HAuCl4) molar ratios. (B) Transmission Electron Microscopy (TEM) image and (C) XRD plot of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs at (AEMA):(HAuCl4) molar ratio of 5. (D) Density profiles of different beads and (E) cross-section views of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs at different (AEMA):(HAuCl4) molar ratios. Reprinted with permission from [139]. Copyright American Chemical Society, 2017.
Figure 7 (A) UV−vis absorption spectra of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs at different (AEMA):(HAuCl4) molar ratios. (B) Transmission Electron Microscopy (TEM) image and (C) XRD plot of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs at (AEMA):(HAuCl4) molar ratio of 5. (D) Density profiles of different beads and (E) cross-section views of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs at different (AEMA):(HAuCl4) molar ratios. Reprinted with permission from [139]. Copyright American Chemical Society, 2017.CC BY · PubMed Central
Figure 8 (A) Loading content, entrapment efficiency and sizes of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs/DOX as a function of mDOX/mmicelle. (B) Density profiles of different beads and (C) cross-section views of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs/DOX micelles at different weight ratios. (D) In vitro drug release profiles of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs/DOX at different pH levels. Reprinted with permission from [139]. Copyright American Chemical Society, 2017.
Figure 8 (A) Loading content, entrapment efficiency and sizes of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs/DOX as a function of mDOX/mmicelle. (B) Density profiles of different beads and (C) cross-section views of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs/DOX micelles at different weight ratios. (D) In vitro drug release profiles of β-CD-(PCL-PAEMA-PPEGMA)21/AuNPs/DOX at different pH levels. Reprinted with permission from [139]. Copyright American Chemical Society, 2017.CC BY · PubMed Central
Figure 9 (a,b) Illustrative description of the strategy used for detecting liver metastatic colorectal tumors using halofluorochromic polymer nanoassemblies (PNAs) and computational simulations. (c,d) Simulation results reflecting the distribution of the nanoparticles in metastatic tumors at (c) 1.8 h and (d) 12 h, after systemic injection of the nanoparticles for three different degrees of vascularization. Red refers to viable tumor tissue, blue reflects enclosing hypoxic tissue, and brown reflects necrotic regions. The rectangular grid represents the capillary network, displaying irregular sprouts, which simulate the angiogenesis effect and the growth of blood vessel. Reprinted with permission from [147]. Copyright Springer Nature, 2017.
Figure 9 (a,b) Illustrative description of the strategy used for detecting liver metastatic colorectal tumors using halofluorochromic polymer nanoassemblies (PNAs) and computational simulations. (c,d) Simulation results reflecting the distribution of the nanoparticles in metastatic tumors at (c) 1.8 h and (d) 12 h, after systemic injection of the nanoparticles for three different degrees of vascularization. Red refers to viable tumor tissue, blue reflects enclosing hypoxic tissue, and brown reflects necrotic regions. The rectangular grid represents the capillary network, displaying irregular sprouts, which simulate the angiogenesis effect and the growth of blood vessel. Reprinted with permission from [147]. Copyright Springer Nature, 2017.CC BY · PubMed Central
Figure 10 (a–c) General procedure of the spectral Fiedler field (SFF) method which includes (a) a raw image in gray scale, (b) the matrix representation of (a), and (c) the resulting contrast matrix. Using the matrix from of each gray scale image, the method is applied to a small region centered at every single pixel, generating the contrast matrix, which is then processed using a low pass filter for removing noise. The final matrix represents the SFF map. (d) Hematoxylin and eosin image of colon tumor. (e) Pattern obtained using CD31 endothelial cell marker. (f) Fluorescence of the drug in tumors. (g) SFF map of echogenic liposomes enhanced ultrasound contrast in tumor areas displaying a positive response for CD31 endothelial cell marker. (h) Relative drug diffusion considering the positive regions in SFF map. (i) Normalized distribution of doxorubicin combined with doxorubicin fluorescence image. Purple shades refer to doxorubicin fluorescence while blue-red corresponds to the spectral shades of doxorubicin distribution. Reprinted from [175] under a CC BY 4.0 License. Copyright Liu, C., Kapoor, A., VanOsdol, J., Ektate, K., Kong, Z., and Ranjan, A., 2018.
Figure 10 (a–c) General procedure of the spectral Fiedler field (SFF) method which includes (a) a raw image in gray scale, (b) the matrix representation of (a), and (c) the resulting contrast matrix. Using the matrix from of each gray scale image, the method is applied to a small region centered at every single pixel, generating the contrast matrix, which is then processed using a low pass filter for removing noise. The final matrix represents the SFF map. (d) Hematoxylin and eosin image of colon tumor. (e) Pattern obtained using CD31 endothelial cell marker. (f) Fluorescence of the drug in tumors. (g) SFF map of echogenic liposomes enhanced ultrasound contrast in tumor areas displaying a positive response for CD31 endothelial cell marker. (h) Relative drug diffusion considering the positive regions in SFF map. (i) Normalized distribution of doxorubicin combined with doxorubicin fluorescence image. Purple shades refer to doxorubicin fluorescence while blue-red corresponds to the spectral shades of doxorubicin distribution. Reprinted from [175] under a CC BY 4.0 License. Copyright Liu, C., Kapoor, A., VanOsdol, J., Ektate, K., Kong, Z., and Ranjan, A., 2018.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 178 references

Research works printed but not linked: 3

  1. Morris, 2018, Big Data, Machine Learning, and Molecular Imaging, J. Nucl. Med., 59, 1159
  2. Chen, X., and Wong, S. (2014). Chapter 2—Genomics-Based Cancer Theranostics. Cancer Theranostics, Academic Press. · DOI
  3. Puri, M., Pathak, Y., Sutariya, V.K., Tipparaju, S., and Moreno, W. (2016). Chapter 14—ANN in Pharmaceutical Product and Process Development. Artificial Neural Network for Drug Design, Delivery and Disposition, Academic Press.

Cited by

See all 33

Metadata

Authors
Cova, T. F. G. G., Bento, D. J., & Nunes, S. C. C.
Affiliations
University of Coimbra (PT)
Corresponding author
  • Cova, Tânia F. G. G.
  • Nunes, Sandra C. C.
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2019-03-13
Volume
11
Issue
3
Pages
119
ISSN
1999-4923 (ISSN-L)
OpenAlex
W2921183732
Cited by
32
References
178
Citations by year
2026: 2 · 2025: 8 · 2024: 4 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 6 · 2019: 2
FWCI
0.33
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Fundação para a Ciência e a Tecnologia (016648 POCI − 01 − 0145 − FEDER − 016648; COMPETE POCI − 01 − 0145 − FEDER − 007440; PEst − OE/QUI/UI0313/2014; POCI − 01 − 0145 − FEDER − 007630; SFRH/BD/95459/2013; SFRH/BPD/71683/2010)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
cancer theranostics, computational modeling, data mining, predictive analytics, machine learning, artificial intelligence, cancer diagnosis, tumor heterogeneity, metastasis, drug resistance, molecular basis of cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Computational Approaches in Theranostics: Mining and Predicting Cancer Data. https://app.cochat.ai/papers/10.3390/pharmaceutics11030119
The paper
Cova, T. F. G. G., Bento, D. J., & Nunes, S. C. C. (2019). Computational Approaches in Theranostics: Mining and Predicting Cancer Data. Pharmaceutics. https://doi.org/10.3390/pharmaceutics11030119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.